Cagrilintide
Cagrilintide
A long-acting amylin analogue studied for appetite reduction and weight loss
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and studied for weight management in obesity. It mimics amylin, a hormone involved in regulating food intake. By activating amylin receptors in the brain, it increases fullness, which is thought to explain the reduced food intake and weight loss seen in trials. As of October 2026, it isn't approved anywhere; it's in Phase 3 trials alone and in CagriSema (with semaglutide), which is under FDA review.
Read the research profile for mechanisms, citations, and safety context before comparing vendors. View the Cagrilintide research profile.
Key Benefits
Mechanism of Action
Cagrilintide activates both amylin and calcitonin receptors, mainly in the area postrema of the brainstem. This strengthens satiety signals, slows gastric emptying and lowers glucagon secretion. The resulting drop in appetite and energy intake is the proposed driver of its effect on body weight.
Dosing Guidelines
Typical Dose
0.3-2.4 mg in trials (Phase 3 used 2.4 mg)
Frequency
1x weekly
Duration
26-68 weeks in trials
Note: Trials gave it by subcutaneous injection. A 2021 Phase 2 trial tested 0.3-4.5 mg weekly for 26 weeks; Phase 3 trials used 2.4 mg weekly after stepwise increases. Users on peptide forums describe starting near 0.25 mg and raising the dose every 2-4 weeks to manage nausea, which is community practice, not a tested protocol.
Research & Studies
Our profile of cagrilintide's mechanism, trial results and reported side effects.
Read Full ResearchIn 706 adults, weekly cagrilintide (0.3-4.5 mg) gave dose-dependent weight loss of 6.0-10.8% at 26 weeks, vs 3.0% on placebo.
Read Full ResearchIn REDEFINE 1 (68 weeks, assuming full adherence), CagriSema gave 22.7% weight loss and cagrilintide alone 11.8%, vs 2.3% on placebo. CagriSema missed non-inferiority against tirzepatide in REDEFINE 4.
Read Full ResearchPotential Side Effects
Reported side effects may include:
- - Nausea (most common in trials, especially during dose increases)
- - Vomiting and/or diarrhea
- - Decreased appetite (an intended effect that can be excessive)
- - Constipation
- - Mild injection site reactions (redness, itching)
- - Dizziness or low mood (user reports)
This information is for research purposes only. Always consult with a healthcare professional.
Popular Stacking Options
Cagrilintide + Semaglutide
The most studied combination (CagriSema, 2.4 mg of each). It roughly doubled the weight loss of cagrilintide alone in REDEFINE 1 but lost to tirzepatide 15 mg in REDEFINE 4 (20.2% vs 23.6% at 84 weeks). Semaglutide is a prescription medicine; research-use versions aren't equivalent.
Shop this stackCagrilintide + Ipamorelin
Some users add it hoping a growth hormone pulse will preserve lean mass during the calorie deficit. No study has tested this combination.
Shop this stackFrequently Asked Questions
How is Cagrilintide different from Semaglutide?
They act on different hormone pathways. Cagrilintide mimics amylin, mainly to reduce appetite. Semaglutide mimics GLP-1 to slow digestion, improve insulin release and also signal fullness to the brain. In trials the combination (CagriSema) produced more weight loss than cagrilintide alone. Semaglutide is an approved prescription medicine; cagrilintide isn't, as of October 2026.
Is the nausea from Cagrilintide manageable?
In the 2021 Phase 2 trial, 20-47% of people on cagrilintide had nausea, vs 18% on placebo. Trials raised the dose gradually (titration), and Novo Nordisk reports that stomach side effects in REDEFINE 1 were mostly mild to moderate and temporary. Users describe nausea easing after a few weeks at a stable dose. Persistent symptoms are a reason to see a healthcare professional.
Can I use Cagrilintide to build muscle?
No, cagrilintide is not an anabolic peptide. It's studied for weight loss through reduced appetite. Fast weight loss can include muscle, which is why some users pair it with peptides like ipamorelin or tesamorelin, though no study has tested those combinations.
How quickly does Cagrilintide work?
Users commonly report appetite changes within the first week or two. In trials, weight loss built gradually: 6.0-10.8% at 26 weeks in the Phase 2 trial, and 11.8% at 68 weeks for cagrilintide alone in REDEFINE 1.
More from this category
Compare nearby options in the same category before choosing a research product.
AOD-9604
Growth hormone fragment studied for fat metabolism
MOTS-c
A mitochondrial-encoded peptide studied in mice for insulin sensitivity and exercise capacity.
Retatrutide
An investigational triple agonist (GIP, GLP-1 and glucagon receptors) studied for weight loss and metabolic health
Semaglutide
A GLP-1 receptor agonist studied for weight management and type 2 diabetes
You might also like
These peptides share research keywords or protocol overlap with Cagrilintide.
Tirzepatide
A dual GIP/GLP-1 receptor agonist studied for weight management and type 2 diabetes
Ready to Purchase Cagrilintide?
Get pharmaceutical-grade Cagrilintide from Simple Peptide with 99%+ purity, third-party lab testing, and same-day dispatch.
Buy Cagrilintide Now